196 related articles for article (PubMed ID: 30566757)
21. Bioavailability of a commercial formulation of ivermectin after subcutaneous administration to sheep.
Canga AG; Sahagun A; Diez MJ; Fernandez N; Sierra M; Garcia JJ
Am J Vet Res; 2007 Jan; 68(1):101-6. PubMed ID: 17199426
[TBL] [Abstract][Full Text] [Related]
22. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Nijenhuis CM; Huitema AD; Marchetti S; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2016 Oct; 56(10):1307-12. PubMed ID: 26918324
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation.
Bernigaud C; Fang F; Fischer K; Lespine A; Aho LS; Mullins AJ; Tecle B; Kelly A; Sutra JF; Moreau F; Lilin T; Beugnet F; Botterel F; Chosidow O; Guillot J
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914951
[TBL] [Abstract][Full Text] [Related]
24. Oral Ivermectin: Regaining a Drug for the Treatment of Scabies.
Blasco Morente G
Actas Dermosifiliogr; 2017 Sep; 108(7):606. PubMed ID: 28554657
[No Abstract] [Full Text] [Related]
25. The effect of food on the pharmacokinetics of oral ivermectin.
Duthaler U; Leisegang R; Karlsson MO; Krähenbühl S; Hammann F
J Antimicrob Chemother; 2020 Feb; 75(2):438-440. PubMed ID: 31691813
[TBL] [Abstract][Full Text] [Related]
26. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies.
Ahmad HM; Abdel-Azim ES; Abdel-Aziz RT
Dermatol Ther; 2016; 29(1):58-63. PubMed ID: 26555785
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.
Sanz-Navarro J; Feal C; Dauden E
Actas Dermosifiliogr; 2017 Sep; 108(7):643-649. PubMed ID: 28385424
[TBL] [Abstract][Full Text] [Related]
29. Comparative plasma disposition, bioavailability and efficacy of ivermectin following oral and pour-on administrations in horses.
Gokbulut C; Cirak VY; Senlik B; Aksit D; Durmaz M; McKellar QA
Vet Parasitol; 2010 May; 170(1-2):120-6. PubMed ID: 20181429
[TBL] [Abstract][Full Text] [Related]
30. Misuse of veterinary wormers in self-medication of rosacea and scabies.
Hellen R; Ní Raghallaigh S
Br J Dermatol; 2019 Apr; 180(4):955. PubMed ID: 30597520
[No Abstract] [Full Text] [Related]
31. Scabies in an obese patient: How should the ivermectin dosing be adapted?
Mellon G; Hermet L; Toutain PL; Dulioust A; Lespine A
Med Mal Infect; 2019 Jun; 49(4):286-288. PubMed ID: 30473320
[No Abstract] [Full Text] [Related]
32. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.
Muñoz J; Ballester MR; Antonijoan RM; Gich I; Rodríguez M; Colli E; Gold S; Krolewiecki AJ
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006020. PubMed ID: 29346388
[TBL] [Abstract][Full Text] [Related]
33. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.
Marks M; Toloka H; Baker C; Kositz C; Asugeni J; Puiahi E; Asugeni R; Azzopardi K; Diau J; Kaldor JM; Romani L; Redman-MacLaren M; MacLaren D; Solomon AW; Mabey DCW; Steer AC
Clin Infect Dis; 2019 Mar; 68(6):927-933. PubMed ID: 29985978
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of ivermectin in pregnant and nonpregnant sheep.
Pérez R; Palma C; Núñez MJ; Cox J; Arboix M
J Vet Pharmacol Ther; 2008 Feb; 31(1):71-6. PubMed ID: 18177322
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.
Guzzo CA; Furtek CI; Porras AG; Chen C; Tipping R; Clineschmidt CM; Sciberras DG; Hsieh JY; Lasseter KC
J Clin Pharmacol; 2002 Oct; 42(10):1122-33. PubMed ID: 12362927
[TBL] [Abstract][Full Text] [Related]
36. Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs.
Eraslan G; Kanbur M; Liman BC; Cam Y; Karabacak M; Altinordulu S
Food Chem Toxicol; 2010; 48(8-9):2181-5. PubMed ID: 20488222
[TBL] [Abstract][Full Text] [Related]
37. Use of ivermectin for the management of scabies in a nursing home.
Dannaoui E; Kiazand A; Piens M; Picot S
Eur J Dermatol; 1999 Sep; 9(6):443-5. PubMed ID: 10491498
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of orally administered ivermectin in African elephants (Loxodonta africana): implications for parasite elimination.
Gandolf AR; Lifschitz A; Stadler C; Watson B; Galvanek L; Ballent M; Lanusse C
J Zoo Wildl Med; 2009 Mar; 40(1):107-12. PubMed ID: 19368248
[TBL] [Abstract][Full Text] [Related]
39. Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults.
Brussee JM; Schulz JD; Coulibaly JT; Keiser J; Pfister M
Clin Pharmacol Ther; 2019 Sep; 106(3):661-667. PubMed ID: 30993667
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
